var data={"title":"Palivizumab: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Palivizumab: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6715?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">see &quot;Palivizumab: Drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205781\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Synagis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205782\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Synagis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049125\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Monoclonal Antibody</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444087\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>RSV, prevention:</b> IM: 15 mg/kg once monthly throughout RSV season; <b>Note:</b> AAP recommends a maximum of 5 doses per season; hospitalized neonates who qualify for prophylaxis during RSV season should receive the first palivizumab dose 48 to 72 hours before discharge or promptly after discharge.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cardiopulmonary bypass patients:</i> IM: Administer a 15 mg/kg dose as soon as possible after cardiopulmonary bypass procedure or at the conclusion of extracorporeal membrane oxygenation, even if &lt;1 month from previous dose. A 58% decrease in palivizumab serum concentrations has been noted after cardiopulmonary bypass (AAP, 2014). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049119\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">see &quot;Palivizumab: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>RSV, prevention:</b> Infants and Children &lt;24 months: IM: 15 mg/kg once monthly throughout RSV season; first dose administered prior to commencement of RSV season; <b>Note:</b> AAP recommends a maximum 5 doses per season; if hospitalization occurs for breakthrough RSV infection, monthly prophylaxis should be discontinued for the remainder of that season (AAP, 2014). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Cardiopulmonary bypass patients:</i> Administer a 15 mg/kg dose as soon as possible after cardiopulmonary bypass procedure or at the conclusion of extracorporeal membrane oxygenation, even if &lt;1 month from previous dose. A 58% decrease in palivizumab serum concentrations has been noted after cardiopulmonary bypass (AAP, 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>RSV, treatment in patients at high-risk for severe disease:</b> Limited data available: Infants, Children, and Adolescents: IV: 15 mg/kg as a single dose; in most patients, used in combination with ribavirin therapy; in two patients with disease progression, a single repeat dose at 3 to 5 days after the initial dose was reported (Ch&aacute;vez-Bueno, 2007). Dosing based on experience in 85 patients the majority of which are pediatric patients and mostly &le;2 years of age. Reported efficacy results variable, an initial double-blind, placebo-controlled trial (n=17 treatment group; all patients &le;2 years) showed statistically significant decreases in RSV tracheal aspirate concentrations vs placebo (Malley, 1998); in another double-blind, placebo-controlled trial (n=22 treatment group; all patients &le;2 years) a decrease in the days of RSV hospitalization, days of supplemental oxygen, and lower respiratory infection scores were reported relative to placebo (S&aacute;ez-Llorens, 2004); in an underpowered, observational study of hematopoietic stem cell  patients (n=15; age range: 2 to 60 years) a decrease viral shedding and increased 30 day-survival vs ribavirin monotherapy (83.3% vs ~55%) was reported (Boeckh, 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants and Children &lt;24 months: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants and Children &lt;24 months: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205766\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synagis: 50 mg/0.5 mL (0.5 mL) [contains glycine, histidine]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synagis: 100 mg/mL (1 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205753\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049128\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Administer undiluted solution IM, preferably in the anterolateral aspect of the thigh; gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve; injection volume over 1 mL should be given as a divided dose. Do <b>not</b> dilute product; do not shake or vigorously agitate the vial.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: In clinical trials in pediatric patients &le;2 years, palivizumab has been administered IVP over 2 to 5 minutes or IV infusion through a 0.2 micron filter at a rate not to exceed 1 to 2 mL/minute at a final concentration of 10 to 20 mg/mL (Boeckh 2001; S&aacute;ez-Llorens 2004; Subramanian 1998).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205779\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store between 2&deg;C and 8&deg;C (36&deg;F and 46&deg;F) in original container; do not freeze. Extended storage information may be available; contact product manufacturer to obtain current recommendations. Discard unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049127\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants and children at high risk for RSV disease including patients with bronchopulmonary disease, a gestational age &le;35 weeks, or hemodynamically significant congenital heart disease (FDA approved &le;24 months of age); has also been used for IV treatment of active RSV infections in patients at high-risk for severe disease. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The American Academy of Pediatrics (AAP, 2014)  recommends RSV prophylaxis with palivizumab during RSV season for: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">&bull; Infants born at &le;28 weeks 6 days gestational age and &lt;12 months at the start of RSV season</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Infants &lt;12 months of age with chronic lung disease (CLD) of prematurity </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Infants &lt;12 months of age with hemodynamically significant congenital heart disease (CHD)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Infants and children &lt;24 months of age with CLD necessitating medical therapy (eg, supplemental oxygen, bronchodilator, diuretic, or chronic steroid therapy) within 6 months prior to the beginning of RSV season</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">AAP also suggests that palivizumab prophylaxis may be considered in the following circumstances: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Infants &lt;12 months of age with congenital airway abnormality or neuromuscular disorder that decreases the ability to manage airway secretions</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Infants &lt;12 months of age with cystic fibrosis with clinical evidence of CLD and/or nutritional compromise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Children &lt;24 months with cystic fibrosis with severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persist when stable) or weight for length less than the 10th percentile.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Infants and children &lt;24 months profoundly immunocompromised </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Infants and children &lt;24 months undergoing cardiac transplantation during RSV season</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205806\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Synagis may be confused with Synalgos-DC, Synflorix, Synvisc</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205804\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis (very rare; includes angioedema, dyspnea, hypotonia, pruritus, respiratory failure, unresponsiveness, urticaria), hypersensitivity reaction, injection site reaction, thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205771\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Significant prior hypersensitivity reaction to palivizumab or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Known hypersensitivity to other humanized monoclonal antibodies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205757\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Anaphylaxis and anaphylactic shock, some fatal cases, have been reported following initial exposure or re-exposure to palivizumab; other acute hypersensitivity reactions (may be severe), have also been reported. If a significant hypersensitivity reaction occurs, permanently discontinue therapy. If anaphylaxis or other significant hypersensitivity reaction occurs, administer appropriate medications (eg, epinephrine) and provide supportive care as required. If a mild hypersensitivity reaction occurs, clinical judgment should be used regarding cautious readministration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Drug-drug interactions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Palivizumab is not recommended for the prevention of health care-associated RSV disease (AAP 2014). Safety and efficacy have not been established for treatment of RSV disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299812\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205762\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12672&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205774\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Not for adult use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049124\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for anaphylactic or severe allergic reactions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205756\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Exhibits neutralizing and fusion-inhibitory activity against RSV; these activities inhibit RSV replication in laboratory and clinical studies</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205770\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Infants and Children &lt;24 months without CHD: 70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Infants and Children &lt;24 months without CHD: 20 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Infants and Children &lt;24 months of age without CHD: ~11 mL/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049132\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Antipalivizumab antibodies may develop after the fourth injection in some patients (~1%).  This has not been associated with any risk of adverse events or altered serum concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323593\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Synagis Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/0.5 mL (0.5 mL): $1,797.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (1 mL): $3,395.06</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205775\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abbosynagis (IL);</li>\n      <li>Synagis (AE, AR, AT, AU, BE, BG, BH, BO, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IQ, IR, IT, JO, JP, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PL, PR, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TR, TW, UY, VE, YE);</li>\n      <li>Synahis (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatric (AAP).  Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. <i>Pediatrics</i>. 2014;134:415-420.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palivizumab-pediatric-drug-information/abstract-text/25070315/pubmed\" target=\"_blank\" id=\"25070315\">25070315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boeckh M, Berrey MM, Bowden RA, et al, &ldquo;Phase 1 Evaluation of the Respiratory Syncytial Virus-Specific Monoclonal Antibody Palivizumab in Recipients of Hematopoietic Stem Cell Transplants,&rdquo; <i>J Infect Dis</i>, 2001, 184(3):350-4. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palivizumab-pediatric-drug-information/abstract-text/11443562/pubmed\" target=\"_blank\" id=\"11443562\">11443562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ch&aacute;vez-Bueno S, Mej&iacute;as A, Merryman RA, et al, &quot;Intravenous Palivizumab and Ribavirin Combination for Respiratory Syncytial Virus Disease in High-Risk Pediatric Patients,&quot; <i>Pediatr Infect Dis J</i>, 2007, 26(12):1089-93. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palivizumab-pediatric-drug-information/abstract-text/18043443/pubmed\" target=\"_blank\" id=\"18043443\">18043443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feltes TF, Cabalka AK, Meissner HC, et al, &ldquo;Palivizumab Prophylaxis Reduces Hospitalization Due to Respiratory Syncytial Virus in Young Children With Hemodynamically Significant Congenital Heart Disease,&rdquo; <i>J Pediatr</i>, 2003, 143(4):532-40. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palivizumab-pediatric-drug-information/abstract-text/14571236/pubmed\" target=\"_blank\" id=\"14571236\">14571236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giebels K, Marcotte JE, Podoba J, et al, &quot;Prophylaxis Against Respiratory Syncytial Virus in Young Children With Cystic Fibrosis,&quot; <i>Pediatr Pulmonol</i>, 2008, 43(2):169-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palivizumab-pediatric-drug-information/abstract-text/18085710/pubmed\" target=\"_blank\" id=\"18085710\">18085710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malley R, DeVincenzo J, Ramilo O, et al, &quot;Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein,&quot; <i>J Infect Dis</i>, 1998, 178(6):1555-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palivizumab-pediatric-drug-information/abstract-text/9815203/pubmed\" target=\"_blank\" id=\"9815203\">9815203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-Risk Infants. The Impact-RSV Study Group,&rdquo; <i>Pediatrics</i>, 1998, 102(3 Pt 1):531-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palivizumab-pediatric-drug-information/abstract-text/9738173/pubmed\" target=\"_blank\" id=\"9738173\">9738173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    S&aacute;ez-Llorens X, Moreno MT, Ramilo O, et al, &quot;Safety and Pharmacokinetics of Palivizumab Therapy in Children Hospitalized With Respiratory Syncytial Virus Infection,&quot; <i>Pediatr Infect Dis J</i>, 2004, 23(8):707-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palivizumab-pediatric-drug-information/abstract-text/15295219/pubmed\" target=\"_blank\" id=\"15295219\">15295219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Subramanian KN, Weisman LE, Rhodes T, et al, &quot;Safety, Tolerance and Pharmacokinetics of a Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants and Infants With Bronchopulmonary Dysplasia. MEDI-493 Study Group,&quot; <i>Pediatr Infect Dis J</i>, 1998, 17(2):110-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palivizumab-pediatric-drug-information/abstract-text/9493805/pubmed\" target=\"_blank\" id=\"9493805\">9493805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synagis (palivizumab) [prescribing information]. Gathersburg, MD: MedImmune, LLC; March 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12672 Version 84.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F205781\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F205782\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049125\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444087\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049119\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F205766\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F205753\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049128\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F205779\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049127\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F205806\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F205804\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F205771\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F205757\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299812\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F205762\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F205774\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049124\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F205756\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F205770\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1049132\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323593\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F205775\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12672|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=palivizumab-drug-information\" class=\"drug drug_general\">Palivizumab: Drug information</a></li></ul></div></div>","javascript":null}